Transcenta News and Activities

Transcenta is a company listed under the stock ticker 6628 (CN).

View the org chart displaying its 14 main executives

Most searched biographies at Transcenta

• Xueming Qian, Chief Executive Officer and Chairman of the Board
• Helen Chen, Independent Non-Executive Director
• Jiasong Tang, Independent Non-Executive Director

Popular executive movements at Transcenta

• Christopher Hwang has joined the company as Head of Global Partnerships, HiCB Platform  (posted on March 31 2026).

Create your alert
to follow the executive moves at Transcenta.

Transcenta has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Transcenta

• Transcenta Reports Receipt of HiCB Out-licensing Milestone Payment and Steady CDMO Business Growth-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta’s Partner Inhibrx Reports Positive Updated CRC Data for Ozekibart and Announces U.S. BLA Submission for Chondrosarcoma-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeuti
• Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-line G/GEJ Cancer at ESMO Asia-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma, with a BLA Submission Planned for 2026-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta Announces the Appointment of Tyler Marciniak as Senior Vice President of Capital Markets, Investor Relations and Corporate Communications-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta Strengthens Promise for Osemitamab (TST001) for G/GEJ Cancer with OS Data from First-Line Triple Combo Trial Unveiled at 2025 ASCO Annual Meeting-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• Transcenta Debuts Promising Anti-Tumor Activity of Novel FGFR2b Targeting ADC with Site-Specific Conjugated Topo I Inhibitor Payload in Preclinical Tumor Models at AACR 2025-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
• View more press releases Close

Social media about Transcenta

• Transcenta on Wikipedia, Google News & Yahoo Finance
• Transcenta on LinkedIn, X (Twitter) & YouTube